Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework Authors: Zihan Cao, Long Meng, Yunlong Li, Mi Zhou, Huiming Jiang, Jun Wang, Yi Tao, Feng Qiu Published: 2026 ABSTRACT IntroductionEndothelin receptor antagonists are important therapies for pulmonary arterial hypertension, but differences in efficacy, safety, monitoring requirements, drug interactions, costs, and accessibility complicate treatment selection.AimTo compare endothelin receptor antagonists across safety, efficacy, economic value, suitability, accessibility, and innovation, and to develop a multidimensional framework for clinical pharmacy decision-making and formulary management.MethodA structured framework was developed through a two-round Delphi process involving 19 multidisciplinary experts. Indicators were classified as quantitative or qualitative and organized into six domains. Consensus was assessed using the authority coefficient, coefficient of variation, and Kendall’s coefficient of concordance. Weights were determined using the analytic hierarchy process and integrated through multi-criteria decision analysis. Quantitative evidence was derived from regulatory sources, randomized trial meta-analysis, national pricing databases, and hospital procurement records. Qualitative indicators, including monitoring requirements, drug interactions, adherence-related factors, accessibility, and innovation, were scored using predefined criteria. Economic value was evaluated in the Chinese healthcare context using annual drug acquisition costs, affordability ratios, and cost per metre improvement in 6-min walk distance.ResultsThe Delphi process established a framework comprising six domains, 13 subdomains, and 32 indicators, with good reliability and consistency: authority coefficient 0.82, Cronbach’s alpha 0.864, and Kendall’s W 0.412. Twelve randomized controlled trials were included in the quantitative synthesis. All endothelin receptor antagonists improved exercise capacity and hemodynamic outcomes, although the magnitude varied. Ambrisentan showed comparatively larger improvements in 6-min walk distance and a trend toward lower odds of adverse drug reactions. Annual drug acquisition costs were ¥24,600 for ambrisentan, ¥17,820 for bosentan, and ¥57,240 for macitentan. The corresponding costs per metre improvement were ¥140.12/m, ¥142.38/m, and ¥1470.71/m, and annual cost-to-income ratios were 87.15%, 63.13%, and 202.78%, respectively. After weighted integration, ambrisentan achieved the highest overall score, followed by bosentan and macitentan.ConclusionWithin the proposed MCDA framework, ambrisentan achieved the highest overall score across multiple clinical and practical dimensions. The framework provides a transparent tool for structured evaluation, although economic and accessibility findings should be interpreted within the Chinese healthcare context.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11096-026-02172-6. Impact statements This study provides a structured framework for clinical pharmacists to evaluate endothelin receptor antagonists across six relevant dimensions.The findings suggest that ambrisentan achieved the highest score within the proposed multidimensional framework when safety, efficacy, economic value, suitability, accessibility, and innovation are considered collectively.This study supports formulary decision-making and value-based prescribing by incorporating multidimensional evidence into routine clinical practice This study provides a structured framework for clinical pharmacists to evaluate endothelin receptor antagonists across six relevant dimensions. This study provides a structured framework for clinical pharmacists to evaluate endothelin receptor antagonists across six relevant dimensions. The findings suggest that ambrisentan achieved the highest score within the proposed multidimensional framework when safety, efficacy, economic value, suitability, accessibility, and innovation are considered collectively. The findings suggest that ambrisentan achieved the highest score within the proposed multidimensional framework when safety, efficacy, economic value, suitability, accessibility, and innovation are considered collectively. This study supports formulary decision-making and value-based prescribing by incorporating multidimensional evidence into routine clinical practice This study supports formulary decision-making and value-based prescribing by incorporating multidimensional evidence into routine clinical practice Introduction Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease characterized by persistently elevated pulmonary artery pressure, ultimately leading to right heart failure and premature death [1, 2]. Despite advances in targeted therapies, PAH remains associated with substantial morbidity, mortality, and long-term treatment burden. Effective management requires sustained pharmacotherapy and careful optimization of treatment strategies. Endothelin receptor antagonists (ERA), including bosentan, ambrisentan, and macitentan, are central components of PAH therapy. By targeting endothelin-1 (ET-1)–mediated pathways, these agents improve hemodynamics, enhance exercise capacity, and delay disease progression [3, 4]. However, despite similar mechanisms of action, ERA differ in safety profiles, monitoring requirements, drug–drug interactions (DDIs) potential, dosing convenience, and cost, all of which influence their use in routine clinical practice. In clinical settings, selecting the most appropriate ERA remains challenging. Treatment decisions must balance efficacy, safety, patient adherence, and economic considerations, particularly in chronic conditions requiring long-term therapy. Clinical pharmacists are increasingly involved in medication therapy management, formulary evaluation, and interdisciplinary decision-making; however, structured and transparent approaches to support these complex decisions remain limited [5]. Traditional single-dimensional evaluations fail to capture the multidimensional value of therapies, highlighting the need for comprehensive and practical assessment tools. Multi-criteria decision analysis has emerged as a useful approach for integrating multiple, and often competing, decision criteria in healthcare. By systematically quantifying and weighting factors such as efficacy, safety, and cost, MCDA enables transparent comparisons of therapeutic alternatives and supports evidence-based, value-oriented decision-making [6, 7]. Incorporating such approaches into clinical pharmacy practice may facilitate rational drug selection, optimize resource allocation, and improve patient outcomes in PAH management. Although MCDA has been increasingly applied in health technology assessment and drug evaluation, particularly for rare diseases and high-cost therapies [6, 7], its application to pulmonary arterial hypertension remains limited. Existing studies have primarily focused on clinical efficacy or safety outcomes of individual therapies [8, 9], with limited integration of multidimensional factors such as economic value, accessibility, and patient-centered considerations. Aim This study aimed to compare endothelin receptor antagonists across six dimensions—safety, efficacy, economic value, suitability, accessibility, and innovation—and to develop a structured multidimensional evaluation framework to support clinical pharmacy decision-making and formulary management in pulmonary arterial hypertension. Method Framework development A multidisciplinary expert panel was convened using a two-round Delphi process to ensure the clinical relevance and methodological rigor of the evaluation framework. Experts were purposively recruited from tertiary hospitals and academic institutions across China, representing clinical pharmacy, cardiology, pulmonology, pharmacoeconomics, and health policy, each possessing at least 10 years of experience in PAH or related fields. Responses were collected anonymously to minimize bias. In total, 19 experts participated in the consensus process. In the first round, experts rated the importance of candidate indicators using a 5-point Likert scale. Indicators were defined as measurable variables representing clinical, economic, or practical aspects of drug evaluation. In the second round, aggregated results were fed back to experts for re-evaluation. Consensus was assessed using the authority coefficient, coefficient of variation, and Kendall’s coefficient of concordance. The framework was developed based on international clinical guidelines, including the 2022 ESC/ERS Guidelines for Pulmonary Hypertension [4], and existing drug evaluation standards [5]. Two rounds of Delphi consultation were conducted. In the first round, experts independently rated the importance and relevance of candidate indicators using a structured questionnaire, and the ratings were aggregated and anonymized. In the second round, experts re-evaluated the indicators based on group ratings, allowing convergence toward consensus. Six key domains reflecting clinical and real-world decision needs were included: safety, efficacy, economic value, suitability, accessibility, and innovation. Within each domain, specific indicators were identified through systematic literature review and expert discussion. These indicators were selected to reflect clinically relevant factors such as adverse drug reactions (ADRs), DDIs, monitoring requirements, treatment costs, and patient adherence considerations. Consensus was assessed using predefined criteria, including the authority coefficient (Cr), coefficient of variation, and Kendall’s coefficient of concordance (W). Indicators were retained when consensus thresholds were met and revised or excluded otherwise. The final framework comprised six domains, 13 subdomains, and 32 indicators, reflecting a hierarchical structure for comprehensive evaluation. Clinical and evidence evaluation Safety and efficacy were evaluated using a combination of regulatory data and evidence synthesis. Drug label information from the U.S. Food and Drug Administration and the China National Medical Products Administration was reviewed to extract key safety characteristics, including ADRs, contraindications, and use in special populations. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess clinical outcomes. A comprehensive literature search was performed in PubMed, Embase, and the Cochrane Library from inception to October 2024. The search strategy combined controlled vocabulary (e.g., MeSH and Emtree terms) and free-text terms related to PAH and ERA. Detailed search strategies for each database are provided in Supplementary Table S1. Eligible studies included RCTs comparing endothelin receptor antagonist monotherapy with placebo in patients with pulmonary arterial hypertension, reporting outcomes such as all-cause mortality, incidence of ADRs, 6-min walk distance (6MWD), and mean pulmonary arterial pressure (mPAP). The 6MWD was included as a key endpoint because it is a clinically meaningful and guideline-recommended measure of functional capacity and treatment response in PAH. A total of 12 RCTs were included in the meta-analysis [10–21] (Supplementary Table S2 and Supplementary Figure S1). Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool, with disagreements resolved by consensus. Efficacy outcomes were synthesized as pooled mean differences (MDs) with 95% confidence intervals (CIs), whereas safety outcomes were summarized as odds ratios (ORs) with 95% CIs using a random-effects model. Economic and patient-centered evaluation Cost data were obtained from publicly available national pricing databases and hospital procurement records, while per capita disposable income was derived from official national statistics. All costs were standardized to 2024 Chinese Yuan. Cost-effectiveness was evaluated based on improvements in 6MWD, a guideline-recommended endpoint reflecting functional capacity in PAH. Economic evaluation included both treatment cost and cost-effectiveness. Annual drug costs were calculated based on recommended dosing and official retail prices. Cost-effectiveness was assessed using the cost-effectiveness analysis (CEA), defined as the cost per unit improvement in 6MWD derived from pooled efficacy data [22, 23]. Lower CEA values indicate greater economic efficiency. Suitability was assessed based on factors relevant to long-term medication use, including dosing frequency, formulation, monitoring requirements, and adherence potential. Accessibility was evaluated based on reimbursement status and affordability, expressed as the ratio of annual out-of-pocket costs to per capita disposable income. Innovation was assessed across clinical, technological, and industrial domains, including therapeutic novelty, target selectivity, and development characteristics. MCDA integration An MCDA approach was used to integrate results across all dimensions [6, 7]. Indicators were standardized to allow comparison across different scales. Quantitative outcomes were normalized based on observed ranges, whereas qualitative indicators were converted into numerical scores using predefined criteria derived from expert consensus. Weights for each indicator were determined using the Analytic Hierarchy Process (AHP) based on expert consensus [24], with higher weights assigned to safety and efficacy reflecting their primary importance in clinical decision-making and guideline-based therapeutic prioritization. Weighted scores were aggregated to generate overall scores for each ERA. Statistical analysis All statistical analyses were conducted using Stata 18.0 and Microsoft Excel 2019. A random-effects model (DerSimonian–Laird method) was applied to account for between-study heterogeneity in meta-analyses [25]. Efficacy outcomes were synthesized as pooled mean differences (MDs) with 95% confidence intervals (CIs), whereas safety outcomes were summarized as odds ratios (ORs) with 95% CIs using a random-effects model. Heterogeneity was assessed using the I2 statistic. Results are presented as forest plots for clinical outcomes and as ranking tables for MCDA results, enabling transparent comparison of the overall clinical value of ERA. Ethics approval This study was strictly conducted in accordance with the principles of the Declaration of Helsinki and, in compliance with the Chinese “Measures for Ethical Review of Life Sciences and Medical Research Involving Human Subjects,” obtained an ethics exemption approval from the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (approval date November 12, 2025). Results Development of the comprehensive evaluation framework A structured evaluation framework for ERA in PAH was established based on Delphi consensus. The final framework comprised six domains, 13 subdomains, and 32 indicators, reflecting a hierarchical structure for comprehensive evaluation. Quality control metrics demonstrated good reliability and consistency (authority coefficient 0.82; Cronbach’s α = 0.864; Kendall’s W = 0.412, P < 0.01). Indicator weights were subsequently determined using the Analytic Hierarchy Process, resulting in a validated multilevel evaluation framework (Table 1). Table 1Multidimensional evaluation framework and weighting of indicators for endothelin receptor antagonistsDomainWeight (%)SubdomainIndicatorWeight (%)Data source/methodSafety26.47Safety evidenceGuideline-based safety evidence5.25Literature/guidelinesBasic safety informationLabel clarity (contraindications, overdose, interactions)2.13Drug labelUse in special populations (e.g., pediatric, pregnancy)2.32Drug labelPharmacovigilance alerts2.41Regulatory dataSafety-related label changes1.42Regulatory dataAll-cause mortality3.18Meta-analysisADR profileADR incidence5.34Meta-analysisADR severity4.42Drug labelEfficacy26.34Evidence strengthGuideline-based treatment position10.32Literature/guidelinesClinical outcomesChange in 6MWD8.59Meta-analysisChange in mPAP7.43Meta-analysisEconomic value15.74Cost-effectivenessCost-effectiveness ratio7.93Statistical analysisCostAnnual treatment cost7.81Statistical analysisSuitability11.37Drug appropriatenessLabel completeness0.63DelphiClinical applicability0.95DelphiRoute and formulation suitability0.84DelphiMonitoring requirements1.22DelphiSpecial device requirement0.86DelphiStorage conditions0.85DelphiUse appropriatenessAdherence potential1.54DelphiDosing schedule1.01DelphiRisk of intolerance1.94DelphiInteraction limitations0.76DelphiEase of contraindication assessment0.77DelphiAccessibility11.25CoverageInsurance reimbursement3.36Policy reviewInclusion in national price negotiation2.23Policy reviewAffordabilityCost-to-income ratio5.66Statistical analysisInnovation8.83Clinical innovationFirst-in-class or novel mechanism2.08Literature/DelphiFulfilment of unmet clinical needs1.64DelphiTechnological innovationTarget selectivity1.78LiteratureFormulation innovation1.54LiteratureIndustrial innovationPatent status1.79LiteratureADR adverse drug reaction, 6MWD 6-min walking distance, mPAP mean pulmonary arterial pressure Table 1Multidimensional evaluation framework and weighting of indicators for endothelin receptor antagonistsDomainWeight (%)SubdomainIndicatorWeight (%)Data source/methodSafety26.47Safety evidenceGuideline-based safety evidence5.25Literature/guidelinesBasic safety informationLabel clarity (contraindications, overdose, interactions)2.13Drug labelUse in special populations (e.g., pediatric, pregnancy)2.32Drug labelPharmacovigilance alerts2.41Regulatory dataSafety-related label changes1.42Regulatory dataAll-cause mortality3.18Meta-analysisADR profileADR incidence5.34Meta-analysisADR severity4.42Drug labelEfficacy26.34Evidence strengthGuideline-based treatment position10.32Literature/guidelinesClinical outcomesChange in 6MWD8.59Meta-analysisChange in mPAP7.43Meta-analysisEconomic value15.74Cost-effectivenessCost-effectiveness ratio7.93Statistical analysisCostAnnual treatment cost7.81Statistical analysisSuitability11.37Drug appropriatenessLabel completeness0.63DelphiClinical applicability0.95DelphiRoute and formulation suitability0.84DelphiMonitoring requirements1.22DelphiSpecial device requirement0.86DelphiStorage conditions0.85DelphiUse appropriatenessAdherence potential1.54DelphiDosing schedule1.01DelphiRisk of intolerance1.94DelphiInteraction limitations0.76DelphiEase of contraindication assessment0.77DelphiAccessibility11.25CoverageInsurance reimbursement3.36Policy reviewInclusion in national price negotiation2.23Policy reviewAffordabilityCost-to-income ratio5.66Statistical analysisInnovation8.83Clinical innovationFirst-in-class or novel mechanism2.08Literature/DelphiFulfilment of unmet clinical needs1.64DelphiTechnological innovationTarget selectivity1.78LiteratureFormulation innovation1.54LiteratureIndustrial innovationPatent status1.79LiteratureADR adverse drug reaction, 6MWD 6-min walking distance, mPAP mean pulmonary arterial pressure Multidimensional evaluation framework and weighting of indicators for endothelin receptor antagonists ADR adverse drug reaction, 6MWD 6-min walking distance, mPAP mean pulmonary arterial pressure Safety evaluation Safety profiles differed across the three ERA (Table 2). Ambrisentan demonstrated fewer clinically relevant DDIs but requires caution in pregnancy and dose adjustment with cyclosporine. Bosentan carries a risk of drug–drug interactions due to induction of CYP3A4 and CYP2C9, and requires routine liver function monitoring, which may increase the treatment burden. Macitentan requires caution with CYP modulators, and its pediatric safety profile remains under investigation. Table 2Guideline recommendations and key safety characteristics of endothelin receptor antagonists in pulmonary arterial hypertensionDrugGuideline/SourceRecommendationKey safety informationAmbrisentanESC/ERS 2022Recommended for low- or intermediate-risk PAH; often combined with tadalafilContraindicated in pregnancy; limited pediatric data; dose adjustment with cyclosporine; moderate CYP interactionsFDA labelIndicated for WHO-FC II–III PAH (idiopathic, hereditary, CTD-associated)Chinese guideline (2021)Improves 6MWD; may be combined with tadalafilBosentanESC/ERS 2022Recommended for WHO-FC II–IV PAHContraindicated in pregnancy and with cyclosporine/glyburide; strong CYP3A4/2C9 inducer; requires liver monitoringFDA labelIndicated for WHO-FC III–IV PAHChinese guideline (2021)Improves exercise capacity, hemodynamics, and clinical outcomesMacitentanESC/ERS 2022Recommended for low- or intermediate-risk PAH; often combined with tadalafilContraindicated with strong CYP modulators; limited pediatric data; requires hepatic/renal monitoring;FDA labelIndicated for WHO-FC II–III PAHChinese guideline (2021)Improves exercise capacity and clinical outcomesPAH pulmonary arterial hypertension, ESC/ERS European Society of Cardiology/European Respiratory Society, FDA U.S. Food and Drug Administration, WHO-FC World Health Organization functional class, CTD connective tissue disease, 6MWD 6-min walk distance, CYP cytochrome P450 Table 2Guideline recommendations and key safety characteristics of endothelin receptor antagonists in pulmonary arterial hypertensionDrugGuideline/SourceRecommendationKey safety informationAmbrisentanESC/ERS 2022Recommended for low- or intermediate-risk PAH; often combined with tadalafilContraindicated in pregnancy; limited pediatric data; dose adjustment with cyclosporine; moderate CYP interactionsFDA labelIndicated for WHO-FC II–III PAH (idiopathic, hereditary, CTD-associated)Chinese guideline (2021)Improves 6MWD; may be combined with tadalafilBosentanESC/ERS 2022Recommended for WHO-FC II–IV PAHContraindicated in pregnancy and with cyclosporine/glyburide; strong CYP3A4/2C9 inducer; requires liver monitoringFDA labelIndicated for WHO-FC III–IV PAHChinese guideline (2021)Improves exercise capacity, hemodynamics, and clinical outcomesMacitentanESC/ERS 2022Recommended for low- or intermediate-risk PAH; often combined with tadalafilContraindicated with strong CYP modulators; limited pediatric data; requires hepatic/renal monitoring;FDA labelIndicated for WHO-FC II–III PAHChinese guideline (2021)Improves exercise capacity and clinical outcomesPAH pulmonary arterial hypertension, ESC/ERS European Society of Cardiology/European Respiratory Society, FDA U.S. Food and Drug Administration, WHO-FC World Health Organization functional class, CTD connective tissue disease, 6MWD 6-min walk distance, CYP cytochrome P450 Guideline recommendations and key safety characteristics of endothelin receptor antagonists in pulmonary arterial hypertension PAH pulmonary arterial hypertension, ESC/ERS European Society of Cardiology/European Respiratory Society, FDA U.S. Food and Drug Administration, WHO-FC World Health Organization functional class, CTD connective tissue disease, 6MWD 6-min walk distance, CYP cytochrome P450 A total of 12 RCTs were included in the final analysis, as illustrated in the PRISMA flow diagram (Supplementary Fig. S1), and all studies were assessed as having a low risk of bias (Supplementary Fig. S2). The meta-analysis indicated that ambrisentan was associated with a lower odds of ADRs (OR 0.57, 95% CI 0.31–1.06), whereas bosentan and macitentan showed higher but non-significant risks. For all-cause mortality, point estimates favored ambrisentan; however, confidence intervals were wide across all agents (Fig. 1). Overall, ambrisentan showed a trend toward a relatively favorable safety and tolerability profile within the included indirect comparisons, although differences did not reach statistical significance.Fig. 1Forest plots of treatment safety of endothelin receptor antagonists in pulmonary arterial hypertension. a Treatment-related adverse drug reactions (ADRs); b all-cause mortality. Results are expressed as pooled odds ratios (ORs) with 95% confidence intervals (CIs) using a random-effects model Forest plots of treatment safety of endothelin receptor antagonists in pulmonary arterial hypertension. a Treatment-related adverse drug reactions (ADRs); b all-cause mortality. Results are expressed as pooled odds ratios (ORs) with 95% confidence intervals (CIs) using a random-effects model Efficacy evaluation All three ERA are recommended as first-line or combination therapies in current PAH guidelines. Meta-analysis confirmed that ERA improve exercise capacity and hemodynamic outcomes, with differences across agents (Fig. 2). For 6MWD, ambrisentan (MD 43.89 m, 95% CI 29.97–57.80) and bosentan (MD 40.95 m, 95% CI 18.02–63.88) were associated with numerically larger improvements in this analysis, whereas macitentan showed a smaller and non-significant improvement (MD 9.73 m, 95% CI − 8.42 to 27.88). For mPAP, bosentan and macitentan showed greater reductions than ambrisentan. These findings suggest that while all ERA provide clinical benefit, differences in efficacy may influence drug selection depending on treatment goals, such as exercise capacity improvement versus hemodynamic control.Fig. 2Forest plots of treatment efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. a Effect on 6-min walk distance (6MWD); b effect on mean pulmonary arterial pressure (mPAP). Results are presented as pooled mean differences with 95% confidence intervals Forest plots of treatment efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. a Effect on 6-min walk distance (6MWD); b effect on mean pulmonary arterial pressure (mPAP). Results are presented as pooled mean differences with 95% confidence intervals Economic evaluation Substantial differences in treatment costs were observed. Annual costs were ¥24,600 for ambrisentan, ¥17,820 for bosentan, and ¥57,240 for macitentan. Cost-effectiveness analysis showed that ambrisentan and bosentan had similar and favorable CEAs (¥140.12/m and ¥142.38/m improvement in 6MWD, respectively), whereas macitentan was associated with a substantially higher CEA (¥1470.71/m). These results indicate that ambrisentan and bosentan provide better economic value, while macitentan may impose a higher financial burden despite clinical benefits. Suitability and accessibility evaluation All ERA demonstrated acceptable labeling completeness and clinical applicability (Table 3). However, differences in dosing and monitoring requirements affected suitability. Ambrisentan and macitentan, both administered once daily, were associated with higher adherence potential. In contrast, bosentan requires twice-daily dosing and more intensive monitoring, which may negatively impact treatment adherence and long-term persistence. Table 3Suitability and accessibility assessment of endothelin receptor antagonists in PAH (score range: 0–2)IndicatorAmbrisentanScoreBosentanScoreMacitentanScoreSuitability Label completenessYes2.0Yes2.0Yes2.0 Clinical applicabilityYes2.0Yes2.0Yes2.0 Route and formulationOral, convenient2.0Oral, convenient2.0Oral, convenient2.0 Monitoring requirementsPeriodic liver monitoring0.8Frequent liver monitoring0.5Periodic monitoring0.9 Special device requirementNone2.0None2.0None2.0 Storage conditionsNo special requirement2.0No special requirement2.0No special requirement2.0 Adherence potentialFavorable1.8Reduced (twice daily)0.8Favorable1.9 Dosing scheduleOnce daily1.6Twice daily1.1Once daily1.7 Risk of intoleranceMild (e.g., edema)1.6Higher (hepatic, anemia)0.3Generally mild1.5 Interaction limitationsAvoid strong CYP inhibitors0.9Multiple CYP interactions1.1Avoid strong CYP inhibitors0.8 Ease of contraindication assessmentYes1.8Yes1.7Yes1.9Accessibility Insurance reimbursementYes2.0Yes2.0Yes2.0 Inclusion in national price negotiationYes2.0Yes2.0Yes2.0 Cost-to-income ratio87.15%0.363.13%0.7202.78%0.0PAH pulmonary arterial hypertension, CYP cytochrome P450 Table 3Suitability and accessibility assessment of endothelin receptor antagonists in PAH (score range: 0–2)IndicatorAmbrisentanScoreBosentanScoreMacitentanScoreSuitability Label completenessYes2.0Yes2.0Yes2.0 Clinical applicabilityYes2.0Yes2.0Yes2.0 Route and formulationOral, convenient2.0Oral, convenient2.0Oral, convenient2.0 Monitoring requirementsPeriodic liver monitoring0.8Frequent liver monitoring0.5Periodic monitoring0.9 Special device requirementNone2.0None2.0None2.0 Storage conditionsNo special requirement2.0No special requirement2.0No special requirement2.0 Adherence potentialFavorable1.8Reduced (twice daily)0.8Favorable1.9 Dosing scheduleOnce daily1.6Twice daily1.1Once daily1.7 Risk of intoleranceMild (e.g., edema)1.6Higher (hepatic, anemia)0.3Generally mild1.5 Interaction limitationsAvoid strong CYP inhibitors0.9Multiple CYP interactions1.1Avoid strong CYP inhibitors0.8 Ease of contraindication assessmentYes1.8Yes1.7Yes1.9Accessibility Insurance reimbursementYes2.0Yes2.0Yes2.0 Inclusion in national price negotiationYes2.0Yes2.0Yes2.0 Cost-to-income ratio87.15%0.363.13%0.7202.78%0.0PAH pulmonary arterial hypertension, CYP cytochrome P450 Suitability and accessibility assessment of endothelin receptor antagonists in PAH (score range: 0–2) PAH pulmonary arterial hypertension, CYP cytochrome P450 All three ERA are included in the Chinese National Reimbursement Drug List (NRDL). However, affordability differed substantially. The annual cost-to-income ratios were 87.15% for ambrisentan, 63.13% for bosentan, and 202.78% for macitentan (Table 3). Despite reimbursement coverage, macitentan remained associated with a significantly higher economic burden, which may limit accessibility in real-world settings. Innovation evaluation From a therapeutic development perspective, bosentan is a first-in-class ERA, whereas ambrisentan and macitentan represent subsequent generations with improved selectivity and pharmacokinetic profiles. Macitentan demonstrated advantages in technological innovation, particularly in receptor binding and pharmacokinetic optimization, whereas ambrisentan showed improvements in safety-related characteristics (Supplementary Table S3). Integrated MCDA results Following integration across all six dimensions, ambrisentan achieved the highest overall score, followed by bosentan and macitentan (Table 4). This ranking reflects the balanced performance of ambrisentan across efficacy, safety, economic value, and suitability, suggesting that it may represent a favorable option under the selected multidimensional evaluation criteria. Detailed MCDA results are provided in Supplementary Table S4. Table 4Overall MCDA scores and ranking of endothelin receptor antagonistsDrugTotal scoreRankAmbrisentan65.841Bosentan64.892Macitentan53.663Total scores were derived from the multi-criteria decision analysis (MCDA) model Table 4Overall MCDA scores and ranking of endothelin receptor antagonistsDrugTotal scoreRankAmbrisentan65.841Bosentan64.892Macitentan53.663Total scores were derived from the multi-criteria decision analysis (MCDA) model Overall MCDA scores and ranking of endothelin receptor antagonists Total scores were derived from the multi-criteria decision analysis (MCDA) model Discussion Comprehensive evaluation framework for rational drug use Optimizing pharmacotherapy in PAH requires balancing efficacy, safety, adherence, and economic considerations in long-term management. Although ERA are central to PAH treatment, structured approaches to support multidimensional comparison and decision-making in clinical practice remain limited. In this study, a comprehensive evaluation framework integrating six domains was applied to assess the overall clinical value of ambrisentan, bosentan, and macitentan. Efficacy and clinical performance of ERA therapies All three ERA are recommended as first-line or combination therapies in current clinical guidelines and represent the backbone of PAH management [4]. Our findings suggested potential differences in treatment effects across ERAs within the current evidence framework. Ambrisentan and bosentan were associated with numerically larger improvements in exercise capacity within the included analyses. The clinical benefit of combination therapy, particularly ambrisentan plus tadalafil, has been well established, with evidence showing reduced risk of clinical failure compared with monotherapy [26]. These findings support current treatment strategies favoring more effective regimens in patients requiring intensified therapy [27]. Safety differentiation and pharmacologic considerations Safety profiles differed substantially across ERA and represent a key factor in treatment selection. Bosentan is associated with hepatotoxicity and significant cytochrome P450 induction, necessitating regular hepatic monitoring. In contrast, ambrisentan and macitentan were associated with fewer safety concerns in the included analyses [28]. From a clinical pharmacy perspective, these differences are highly relevant, as adverse events and drug interactions directly influence medication review, patient counseling, and ongoing therapy management. In special populations, bosentan has more established pediatric data, whereas evidence for newer ERA remains limited. All ERA are contraindicated during pregnancy, highlighting the importance of pharmacist-led risk counseling and monitoring. Economic value and affordability Economic evaluation showed that, despite reimbursement coverage, ERA therapy remains associated with substantial costs. Ambrisentan and bosentan demonstrated more favorable cost-effectiveness profiles, whereas macitentan was associated with higher costs and less favorable CEAs. These findings underscore the importance of integrating cost-effectiveness into clinical decision-making. As healthcare systems increasingly adopt value-based care models, such evidence is essential for formulary evaluation and reimbursement decisions [29]. Importantly, economic considerations must be balanced with clinical benefit to ensure both affordability and optimal patient outcomes. Suitability, adherence, and real-world implications Suitability and adherence are critical determinants of long-term treatment success in PAH. Ambrisentan and macitentan, with once-daily dosing and improved tolerability, demonstrated advantages over bosentan, which requires more frequent dosing and monitoring. These findings are consistent with long-term clinical evidence suggesting improved treatment persistence with newer ERA [27]. From a clinical pharmacy perspective, factors such as dosing convenience, monitoring burden, and tolerability play a central role in optimizing adherence and ensuring sustained therapeutic benefit. Innovation and therapeutic evolution The evolution of ERA reflects progressive improvements in pharmacological design. Bosentan, as a first-in-class agent, established the therapeutic pathway, whereas ambrisentan and macitentan introduced improvements in receptor selectivity, pharmacokinetics, and safety. While macitentan demonstrated advantages in innovation, these did not fully translate into superior overall clinical value when economic and practical considerations were incorporated, highlighting the importance of multidimensional evaluation beyond pharmacological advancement alone. Clinical pharmacy and policy implications This study highlights the important role of clinical pharmacists in supporting rational drug selection and formulary decision-making. By integrating evidence on efficacy, safety, and economic outcomes, pharmacists can contribute to multidisciplinary decision-making and optimize medication use. The proposed multidimensional evaluation approach provides a practical tool that can be applied in clinical pharmacy practice and hospital Drug and Therapeutics (D&T) committees. Such structured approaches may enhance transparency, support value-based prescribing, and facilitate alignment between clinical evidence and healthcare policy. Overall interpretation and study limitations Overall, within the present MCDA framework, ambrisentan achieved the highest overall score across efficacy, safety, cost-effectiveness, and suitability, suggesting that it may represent a favorable option when multiple clinical and practical factors are considered. However, treatment decisions should remain individualized based on patient characteristics, comorbidities, and treatment preferences. Importantly, comparisons across endothelin receptor antagonists in this study were indirect and were not based on head-to-head randomized controlled trials or formal network meta-analysis. Therefore, differences observed between agents should be interpreted cautiously and should not be considered definitive evidence of comparative clinical superiority. Several limitations should be acknowledged. First, the economic evaluation used 6MWD as a surrogate effectiveness outcome rather than quality-adjusted life years (QALYs). Although 6MWD is a guideline-recommended and clinically meaningful measure in PAH, it does not capture long-term survival or health-related quality-of-life benefits; therefore, the findings should be interpreted as comparative rather than definitive economic evaluations. Second, the analysis was primarily based on published RCTs, and real-world effectiveness may differ across populations and healthcare systems. Third, economic inputs were derived from a specific healthcare context, which may limit generalizability. Fourth, although a structured Delphi process was applied, the use of expert-based weighting in MCDA framework may still introduce a degree of subjectivity. Finally, the proposed evaluation framework requires further validation in prospective, multicenter settings, and future studies incorporating real-world data and more comprehensive pharmacoeconomic modeling may further refine this approach. Therefore, the ranking generated by the MCDA framework should be interpreted as a structured decision-support result rather than definitive comparative evidence of clinical superiority. Conclusion This study offers multidimensional comparison of endothelin receptor antagonists in pulmonary arterial hypertension, integrating clinical, safety, and economic outcomes. Within the present MCDA framework, ambrisentan achieved the highest overall score, reflecting a relatively balanced performance across efficacy, safety, economic value, and treatment suitability. These findings suggest that ambrisentan may represent a favorable option when multiple decision dimensions are considered simultaneously. The proposed approach offers a practical tool for clinical pharmacists and healthcare decision-makers to support rational drug selection and value-based prescribing. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 17 KB)Supplementary file2 (DOCX 31 KB)Supplementary file3 (DOCX 29 KB)Supplementary file4 (DOCX 32 KB) Supplementary file1 (DOCX 17 KB) Supplementary file2 (DOCX 31 KB) Supplementary file3 (DOCX 29 KB) Supplementary file4 (DOCX 32 KB)